It is important to mention that our innovative dual‐gene deletion technology (ANC@RNP/crEGFR‐PLK1) achieved a median survival period of 55 days, which is significantly higher than the 32 days reported with the typical clinical standard temozolomide (TMZ) in our prior examination on GBM treatment.[2a] The size of excised glioma tissue taken from mice treated with ANC@RNP/crEGFR‐PLK1 was consistently smaller than tumor tissue taken from controls (Figure 4e). The gene discussed is PLK1; the disease is glioma.